Invention Grant
- Patent Title: Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
-
Application No.: US15510138Application Date: 2014-09-11
-
Publication No.: US10538555B2Publication Date: 2020-01-21
- Inventor: Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Kevin W. Gillman , Qian Zhao , Katharine A. Grant-Young , Paul Michael Scola , Lyndon A. M. Cornelius
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2014/055093 WO 20140911
- International Announcement: WO2016/039749 WO 20160317
- Main IPC: A61K38/12
- IPC: A61K38/12 ; C07K7/64 ; C07K7/08 ; A61K45/06 ; A61K38/00
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Public/Granted literature
- US20170260237A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS Public/Granted day:2017-09-14
Information query
IPC分类:
